The logic behind the approach rests on a decade of progress in proteomics, the large-scale study of the protein complement of biological systems. Unlike the genome, which is essentially fixed at conception, the proteome is dynamic: it shifts with infection, stress, exercise, disease, and, crucially, with age itself. Researchers have shown that machine-learning models trained on thousands of plasma protein measurements can predict chronological age with remarkable accuracy, and that the difference between predicted and actual age—sometimes called proteomic age acceleration—correlates with frailty, multimorbidity, and mortality risk. These proteomic clocks are conceptually analogous to the epigenetic clocks based on DNA methylation that transformed aging research in the 2010s, but they offer distinct advantages for interventional trials: blood proteins are readily sampled repeatedly, they respond to physiological change on shorter timescales than DNA methylation marks, and many of the proteins involved are themselves drug targets or biomarkers already familiar to the pharmaceutical industry.

What the new study demonstrates is that this technology can survive contact with the realities of clinical trial design. The researchers integrated multiple proteomic aging clocks into the analytical framework of a phase 2a trial, the earliest stage at which a therapeutic candidate is tested in patients or at-risk volunteers to gather preliminary evidence of biological activity. Rather than treating biological age estimation as an exploratory afterthought, the team built the clocks into the statistical evaluation plan from the outset, defining in advance how changes in proteomic age would be measured, how measurement noise would be handled, and how multiple clock outputs could be combined to give a coherent picture of whether an intervention was shifting the biology of aging in a favorable direction.

The emphasis on simultaneous assessment is the study’s most distinctive contribution. Different aging clocks, trained on different protein sets and different cohorts, capture partly overlapping and partly distinct facets of the aging process—one model may be more sensitive to inflammatory pathways, another to metabolic or hepatic changes, a third to renal or cardiovascular decline. By deploying a suite of clocks in parallel rather than betting on a single algorithm, the trial design allows investigators to ask not merely whether an intervention changes a number, but whether it changes the underlying biology in a way that is consistent across independent measures of aging. Convergence across multiple clocks provides a form of internal replication that a single biomarker cannot offer, while divergence among clocks can itself be informative, pointing to organ-specific or pathway-specific effects that would otherwise be invisible.

Technically, the integration demanded solutions to several stubborn problems. Proteomic measurements are sensitive to pre-analytical variables: the choice of assay platform, the timing of blood draws, fasting status, and even the season of sample collection can shift protein concentrations. Longitudinal interpretation requires that the analytical pipeline distinguish true within-person change from batch effects and ordinary biological fluctuation. The study addressed these challenges by anchoring the clocks to repeated baseline sampling, applying rigorous quality control to the proteomic data, and using statistical models that estimate change within individuals rather than relying solely on comparisons between treatment and control groups at a single time point. This within-person framing is essential for short trials, because it dramatically increases statistical power when each participant serves as their own reference for the direction and magnitude of biological aging.

The broader significance of the work lies in what it could do to the economics of geroscience. Developing drugs that target aging has long been caught in a regulatory and commercial Catch-22: regulators generally approve treatments for diseases, not for aging itself, because aging lacks an agreed clinical endpoint; without approved indications, investment in geroprotective therapies has lagged. Biomarkers that can credibly demonstrate a slowing of biological aging over months rather than decades offer a path through this impasse. If proteomic clocks can be validated as surrogate endpoints or at least as robust pharmacodynamic markers, early-phase trials of candidate geroprotectors—whether repurposed drugs such as rapamycin and its analogues, senolytic agents that clear senescent cells, or novel molecules designed around aging pathways—become faster, smaller, and far cheaper to run.

The phase 2a setting is precisely where such markers earn their keep. Phase 2a studies are designed to detect signals of biological activity, not to prove clinical benefit, and a biomarker that reliably responds to an intervention’s mechanism of action is exactly the kind of signal these trials exist to find. Embedding proteomic clocks at this stage creates a screening funnel: interventions that show consistent effects across multiple aging measures can be advanced to larger trials with confidence, while those that leave the proteome untouched can be deprioritized before expensive late-stage development. In effect, the clocks function as a biological readout of geroprotection, analogous to how viral load measurements transformed the early development of antiretroviral therapies.

Important caveats remain, and the authors and the field are careful to acknowledge them. A change in a proteomic aging clock is not yet proof that a therapy extends healthspan or lifespan; the clocks are validated against age-related outcomes in observational data, and demonstrating that an intervention moves the biomarker is only the first step toward showing that it changes disease trajectories. Calibration across diverse populations is another open question, since proteomic aging signatures can vary with ancestry, sex, socioeconomic factors, and baseline health status, and a clock optimized in one cohort may miscalibrate in another. Standardization across assay platforms and laboratories will also be necessary before proteomic age becomes a measure that regulators and clinicians can compare across studies. The new work does not resolve these issues single-handedly, but it establishes a concrete, tested framework within which they can be addressed trial by trial.

Even so, the moment feels like an inflection point. The geroscience field has spent years generating compelling animal data on interventions that delay aging, only to face a translational bottleneck at the human frontier. The integration of proteomic aging clocks into a real phase 2a clinical trial shows that the measurement problem—long the field’s most fundamental limitation—is tractable with current technology. If subsequent trials replicate and extend this framework, the result could be a virtuous cycle in which better biomarkers enable faster trials, faster trials attract greater investment, and greater investment produces the interventions that finally move the needle on human healthspan. Aging, for the first time, is being measured in the clinic on the timescale of a clinical trial, and that change may prove as important as any single therapeutic candidate now in development.

Subject of Research: Proteomic aging clocks integrated into a phase 2a clinical trial for geroprotective assessment

Article Title: Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment

Article References: Zhavoronkov, A., Galkin, F., Chen, S., Ren, F., Aliper, A., Durymanov, M., Sidorenko, D., Cui, H., Han, J.-D. J., Xu, H., Liu, X., Xu, Z., Kuppe, C., Austin Argentieri, M., Ying, K., Goeminne, L. J. E., Moqri, M., Tyshkovskiy, A., & Gladyshev, V. N. (2026). Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03286-y

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03286-y

Keywords: proteomic aging clocks, biological age, geroprotection, phase 2a trial, geroscience, biomarkers, plasma proteomics, aging interventions, healthspan, clinical trial design, machine learning, surrogate endpoints

At the heart of this breakthrough lies the integration of two complex biological data sets: the IgG N-glycome and the blood transcriptome. The IgG N-glycome pertains to the intricate sugar structures covalently attached to immunoglobulin G (IgG) antibodies. These glycan modifications play key roles in immune function and have been shown to evolve with age, reflecting immune system remodeling and systemic physiological changes. On the other hand, the transcriptome captures a snapshot of active gene expression within blood cells at any given moment, offering a dynamic overview of cellular activity and responses to internal and external stimuli. By examining these two layers together, the researchers aimed to encapsulate a more holistic fingerprint of biological aging.

Developing a tool capable of synergizing these complex data types was a formidable challenge, expertly addressed through the application of Deep Reinforcement Learning, a sophisticated form of artificial intelligence where algorithms iteratively learn optimal decision-making strategies from interacting with the data environment. This approach led to the creation of an ageing clock dubbed “gtAge,” a model that comprehensively interprets multi-omics inputs to predict biological age. Dr Xingang Li, a leading co-author and Postdoctoral Research Fellow at ECU, elucidated that gtAge can predict chronological age with a remarkable 85.3% accuracy, substantially surpassing previous models that relied solely on either glycomic or transcriptomic data.

The implications of this enhanced precision are profound. The model calculates what is known as the “delta age,” the discrepancy between predicted biological age and actual chronological age. This delta age correlates significantly with well-established markers of health and aging, including cholesterol levels, glucose metabolism, and other cardiovascular and metabolic indicators. Such linkage suggests that gtAge not only measures aging but also provides an actionable metric related to an individual’s real health risks, offering a potential early diagnostic tool for age-associated diseases.

Dr Li highlighted the critical limitation of relying exclusively on chronological age, pointing out its inability to capture the heterogeneity in aging observed across individuals. While some people experience pronounced physical and cognitive decline in their 60s or 70s, others maintain robust health well into nonagenarian years. This variation is attributable to differences in biological age driven by genetics, lifestyle, nutritional status, and disease history, emphasizing the need for a metric like gtAge that reflects these nuanced factors.

The development of gtAge also underscores a triumph of interdisciplinary collaboration. ECU’s Dr Syed Islam, a Senior Lecturer in Computer Science, led the AI methodology. His team engineered a custom AI tool named “AlphaSnake,” which harnesses Deep Reinforcement Learning to intelligently select the most informative features from the multi-omics datasets, avoiding the traditional pitfalls of naïvely merging heterogeneous data. The algorithm effectively navigates the complex biological landscape, balancing signal extraction while minimizing noise and redundancy, thus optimizing the age prediction model.

Testing the model rigorously, the researchers applied gtAge to a cohort of 302 middle-aged adults participating in the Busselton Healthy Ageing Study in Western Australia. This study population provided a valuable landscape to evaluate the tool’s robustness across a typical demographic range. Findings demonstrated that gtAge not only reflected chronological age with high fidelity but also linked with biological markers indicative of health status, reinforcing its potential clinical utility.

In context, Australia’s population dynamics—marked by rising elderly demographics—amplify the relevance of such a tool. The ability to assess biological age precisely allows healthcare practitioners to identify patients at elevated risk of age-dependent disorders earlier, enabling timely intervention strategies that could delay or prevent disease onset. Dr Islam emphasized the prospective public health benefits, where early lifestyle modifications informed by biological age measurements could markedly improve quality of life and reduce healthcare burdens.

Importantly, the concept of an aging clock is not new, yet previous iterations struggled with limited accuracy, often due to reliance on single data types or insufficient integration methods. The gtAge clock sets a new benchmark by leveraging multi-omics integration facilitated through a novel AI framework, thus providing a richer, more accurate picture of aging biology that captures the multifaceted nature of the process.

Beyond predicting age, this multifactorial approach opens the door for uncovering mechanisms that drive aging at a molecular level. The integration of glycomic and transcriptomic data provides insights into immune modulation, inflammatory status, and genetic regulation affecting aging pathways. Such mechanistic understanding could inform drug discovery, therapeutic targeting, and the design of personalized anti-aging interventions.

Looking forward, the research team envisions expanding the utility of gtAge through larger, more diverse population studies and longitudinal tracking to monitor how biological age changes over time in response to interventions. This could enrich its predictive power and verify its role as a dynamic health biomarker. Furthermore, integrating additional omics layers, such as proteomics or metabolomics, may refine and enhance the model’s sensitivity and specificity.

The study detailing this advance, titled “Deep Reinforcement Learning–Driven Multi-Omics Integration for Constructing gtAge: A Novel Aging Clock from IgG N-glycome and Blood Transcriptome,” was published in the journal Engineering on August 19, 2025. The authors’ transparent declaration asserts no competing financial interests, affirming the integrity of their findings.

In summary, this transformative work represents a milestone in aging research and precision medicine. As technologies converge and sophisticated AI models emerge, tools like gtAge provide an empowering lens for clinicians and individuals alike to understand biological aging beyond the passage of time. By translating complex biological data into meaningful health insights, this innovation holds the promise of fostering healthier lifespans and reshaping ageing from an inevitable decline to a manageable, informed journey.

Subject of Research: Cells

Article Title: Deep Reinforcement Learning–Driven Multi-Omics Integration for Constructing gtAge: A Novel Aging Clock from IgG N-glycome and Blood Transcriptome

News Publication Date: 19-Aug-2025

Web References:
https://www.sciencedirect.com/science/article/pii/S2095809925004837?via%3Dihub
http://dx.doi.org/10.1016/j.eng.2025.08.016

References:
Li, X., Islam, S., Xia, Y., Baten, A., Tan, X., & Wang, W. (2025). Deep Reinforcement Learning–Driven Multi-Omics Integration for Constructing gtAge: A Novel Aging Clock from IgG N-glycome and Blood Transcriptome. Engineering. https://doi.org/10.1016/j.eng.2025.08.016

Keywords:
Biological age, Aging clock, IgG N-glycome, Blood transcriptome, Deep reinforcement learning, Multi-omics integration, Artificial intelligence, Machine learning, Precision medicine, Age-related diseases

The impetus behind invigorating biomarker discovery springs from an urgent clinical and societal need. Chronological age alone is insufficient in capturing the heterogeneity of aging among individuals. Biological age—an aggregate reflection of physiological decline and damage accumulation—requires robust, reliable, and clinically actionable biomarkers that can forecast disease risk, track therapeutic interventions, and ultimately guide personalized health strategies. Jacques et al. embark on this challenge by synthesizing interdisciplinary methodologies that transcend traditional markers, such as telomere length or inflammatory profiles, moving toward integrative molecular signatures with enhanced sensitivity and specificity.

Central to their approach is the deployment of high-throughput multi-omics technologies, encompassing genomics, epigenomics, transcriptomics, proteomics, and metabolomics. By integrating data streams from these diverse but complementary domains, the researchers have crafted composite biomarker profiles that capture systemic aging processes at multiple biological scales. Their analytical pipeline employs sophisticated machine learning algorithms capable of disentangling age-related signals from confounding variables such as lifestyle, environmental exposures, and comorbidities. This computational rigor ensures biomarker robustness, reproducibility across cohorts, and adaptability for diverse populations.

One of the pivotal innovations highlighted in the research is the refinement of epigenetic clocks. While earlier models based on DNA methylation patterns offered promising age-prediction accuracy, Jacques and colleagues have enhanced these clocks by incorporating novel CpG sites linked to mechanistic aging pathways, including cellular senescence and DNA damage response. These advanced clocks demonstrate superior predictive power not only for chronological age but also for biological functions, such as immune competence and regenerative capacity, thereby bridging the gap between molecular measurements and physiological outcomes.

Beyond identifying biomarkers, the study tackles the equally challenging task of clinical translation. The authors underscore the necessity of standardizing biomarker assays for routine use, emphasizing scalability, cost-effectiveness, and minimal invasiveness. For instance, they report progress toward blood-based biomarker panels that require only small volumes of plasma or serum, facilitating integration into regular health assessments. Moreover, by correlating biomarker dynamics with longitudinal clinical data, the research delineates how these molecular indices can forecast onset and progression of age-related diseases such as cardiovascular disorders, neurodegeneration, and metabolic syndrome.

A particularly compelling aspect of this work is the exploration of biomarkers’ utility in monitoring the efficacy of geroprotective interventions. By quantifying biological age changes in response to therapeutic strategies—ranging from caloric restriction mimetics and senolytics to physical exercise regimens—the study paves the way for adaptive and personalized aging management. This paradigm shift moves geriatrics from a reactive to a proactive discipline, leveraging molecular insights to delay or even reverse deleterious aging trajectories.

The implications of this research also extend to drug development pipelines, where validated aging biomarkers can serve as surrogate endpoints in clinical trials. This innovation holds promise to expedite evaluation of candidate compounds, mitigate costs, and improve regulatory pathways. With aging recognized increasingly as a modifiable risk factor, regulatory agencies have shown growing interest in biomarker-guided approvals, making the findings by Jacques et al. not merely academic but poised to influence health policy and pharmaceutical innovation.

Another critical dimension addressed is the ethical and societal implications of implementing aging biomarkers. The authors advocate for responsible deployment, cautioning against potential misuse, such as discrimination in insurance or employment based on biological age. They call for establishing frameworks that ensure equitable access and safeguard individual privacy, underscoring that the technological sophistication of biomarker tools must be matched with ethical stewardship.

In supporting the reproducibility and transparency of their work, Jacques and colleagues have provided open-source computational tools and extensive datasets from diverse cohorts, enhancing collaborative efforts worldwide. This openness fosters cross-validation and refinement by independent research groups, accelerating collective advancement. The study’s multi-institutional collaboration exemplifies the power of integrating expertise across molecular biology, bioinformatics, clinical sciences, and ethics.

Technological evolution remains integral to future advances. The authors speculate on emerging modalities such as single-cell multi-omics, spatial transcriptomics, and deep phenotyping to deepen biomarker precision, uncovering cellular heterogeneity and tissue-specific aging patterns. Coupled with wearable sensors and digital health platforms, there is potential to blend molecular aging metrics with real-time physiological data, creating dynamic models of aging that guide timely interventions.

Importantly, the publication situates these scientific breakthroughs within the broader context of population health. Aging biomarkers could revolutionize epidemiological monitoring, enabling public health officials to identify at-risk subpopulations and tailor preventive measures accordingly. This precision public health approach could alleviate burdens on healthcare systems by shifting focus from disease treatment to health span extension.

Despite these strides, challenges remain. The complexity of aging, influenced by genetic, epigenetic, environmental, and stochastic factors, demands biomarkers that reflect this multifactorial nature. The study acknowledges the need for continued validation across different ethnicities, sexes, and socioeconomic backgrounds to ensure universal applicability and avoid exacerbating health disparities.

In summary, Jacques, Herzog, Ying, and colleagues deliver a masterful and comprehensive examination of aging biomarker discovery and translation, offering an unprecedented toolkit for unlocking the mysteries of aging. Their integrated multi-omics strategies, combined with rigorous computational models and translational foresight, set a new standard for geroscience research. As the field moves toward clinical reality, this work heralds a future where biological age is quantifiable, modifiable, and harnessed to enhance human health and longevity.

This publication represents a milestone not only in aging research but also in personalized medicine. By facilitating early detection of aging-related pathologies and enabling individualized therapeutic regimens, these advances promise to transform healthcare paradigms. The capacity to measure and modulate the aging process could redefine concepts of disease, wellness, and lifespan itself.

The scientific community eagerly anticipates further validation studies and the rollout of biomarker-guided clinical trials inspired by this work. Ultimately, the confluence of molecular biology, data science, and clinical innovation in this study illuminates a path toward achieving healthy aging at scale, a goal of profound human and societal significance.

Subject of Research:
Discovery and clinical translation of biomarkers for aging.

Article Title:
Invigorating discovery and clinical translation of aging biomarkers.

Article References:
Jacques, E., Herzog, C., Ying, K. et al. Invigorating discovery and clinical translation of aging biomarkers. Nat Aging 5, 539–543 (2025). https://doi.org/10.1038/s43587-025-00838-w

Image Credits:
AI Generated